Synthesis, characterization, molecular docking and biological activities of novel pyrazoline derivatives


Turkan F., Cetin A., Taslimi P., Karaman H. S. , GÜLÇİN İ.

ARCHIV DER PHARMAZIE, vol.352, no.6, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 352 Issue: 6
  • Publication Date: 2019
  • Doi Number: 10.1002/ardp.201800359
  • Journal Name: ARCHIV DER PHARMAZIE
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Keywords: acetylcholinesterase, enzyme inhibition, human carbonic anhydrase, in silico study, induced fit docking, pyrazoline, ANHYDRASE ISOENZYMES I, GLUTATHIONE-S-TRANSFERASE, CARBONIC-ANHYDRASE, INHIBITORY PROPERTIES, MANNICH-BASES, 1ST SYNTHESIS, ACETYLCHOLINESTERASE, BUTYRYLCHOLINESTERASE, BROMOPHENOLS, ANTIOXIDANT

Abstract

In this study, synthesis of ethyl 2-((4-bromophenyl)diazenyl)-3-oxo-phenylpropanoate 1 was carried out and a series of new 3H-pyrazol-3-ones (P1-7) were synthesized from 1 as well as various hydrazines. The obtained yields of the synthesized compounds were moderate (40-70%) and these compounds were confirmed by spectral data. These novel pyrazoline derivatives were effective inhibitor compounds of the human carbonic anhydrase I and II isozymes (hCAs I and II) and of the acetylcholinesterase (AChE) enzyme, with K-i values in the range of 17.4-40.7 nM for hCA I, 16.1-55.2 nM for hCA II, and 48.2-84.1 nM for AChE. In silico studies were performed on the compounds inhibiting hCA I, hCA II, and AChE receptors. On the basis of the findings, the inhibition profile of the new pyrazoline compounds at the receptors was determined.